TY - CHAP M1 - Book, Section TI - Chapter 445. Chemotherapy and Radiation Therapy A1 - Adamson, Peter C. A1 - Kun, Larry E. A2 - Rudolph, Colin D. A2 - Rudolph, Abraham M. A2 - Lister, George E. A2 - First, Lewis R. A2 - Gershon, Anne A. PY - 2011 T2 - Rudolph's Pediatrics, 22e AB - Over the last four decades of the 20th century, the cure rates for childhood cancer increased from less than 30% to almost 80%.1 Remarkably, most of the advances did not occur from the discovery of new drugs; rather, they came from a better understanding of the underlying biology of childhood cancers; from improvements in the supportive care necessary for the delivery of multimodality therapy; and from improvements in our understanding and use of chemotherapy, radiotherapy, and surgery. The turn of the century saw the introduction of molecularly targeted therapy, heralded by the development of imatinib mesylate (Gleevec) for the treatment of chronic myelogenous leukemia.2 Even as new molecularly targeted therapies emerge, the success of cytotoxic chemotherapy, coupled with the accumulating data of the potential value of integrating molecularly targeted therapies with classic cytotoxic drugs,3 suggests that the chemotherapeutic drugs and radiotherapeutic modalities utilized today are likely to remain the foundation of therapy for the foreseeable future. Advances in radiation delivery have improved the therapeutic ratio in children, enabling safer use of conformal radiation techniques that better spare the developing normal tissues. An understanding of the principles of therapy and management of the inherent toxicities of cancer therapy are therefore important for pediatricians today. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/04/19 UR - accesspediatrics.mhmedical.com/content.aspx?aid=7041738 ER -